Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uwe Wagner

Showing results (171-180 of 209) with videos related to

Pageof 21
Sort By:
Blood|February 12, 2017
Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodentsMalte Asshoff, Verena Petzer, Matthew R Warr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2006
Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers OvariensAndreas du Bois, Beatrice Weber, Justine Rochon, et al.
Oncotarget|May 14, 2015
Deregulation of PPARβ/δ target genes in tumor-associated macrophages by fatty acid ligands in the ovarian cancer microenvironmentTim Schumann, Till Adhikary, Annika Wortmann, et al.
Nature Communications|April 10, 2015
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targetsAgnieszka K Witkiewicz, Elizabeth A McMillan, Uthra Balaji, et al.
American Journal of Translational Research|March 23, 2019
Loss of Jak2 protects cardiac allografts from chronic rejection by attenuating Th1 response along with increased regulatory T cellsHassan Mohammed Khair Ibrahim Higazi, Long He, Jing Fang, et al.
Breast Cancer Research : BCR|July 7, 2025
Overexpression of TSG101 causes the development of adenosquamous mammary carcinomaRayane Dennaoui, Patrick D Rädler, Madison N Wicker, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 17, 2020
LION-PAW (lymphadenectomy in ovarian neoplasm) sexual function assessment: a prospective sub-study of the LION trialAnnette Hasenburg, Jalid Sehouli, Bjoern Lampe, et al.
Iscience|December 4, 2023
TRAIL-dependent apoptosis of peritoneal mesothelial cells by NK cells promotes ovarian cancer invasionAnna Mary Steitz, Clarissa Schröder, Isabel Knuth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapseEric Pujade-Lauraine, Uwe Wagner, Elisabeth Aavall-Lundqvist, et al.
Molecular Oncology|October 25, 2018
Cell type-selective pathways and clinical associations of lysophosphatidic acid biosynthesis and signaling in the ovarian cancer microenvironmentSilke Reinartz, Sonja Lieber, Jelena Pesek, et al.
Pageof 21

Showing results (171-180 of 209) with videos related to

Sort By:
Pageof 21
Blood|February 12, 2017
Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodentsMalte Asshoff, Verena Petzer, Matthew R Warr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2006
Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers OvariensAndreas du Bois, Beatrice Weber, Justine Rochon, et al.
Oncotarget|May 14, 2015
Deregulation of PPARβ/δ target genes in tumor-associated macrophages by fatty acid ligands in the ovarian cancer microenvironmentTim Schumann, Till Adhikary, Annika Wortmann, et al.
Nature Communications|April 10, 2015
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targetsAgnieszka K Witkiewicz, Elizabeth A McMillan, Uthra Balaji, et al.
American Journal of Translational Research|March 23, 2019
Loss of Jak2 protects cardiac allografts from chronic rejection by attenuating Th1 response along with increased regulatory T cellsHassan Mohammed Khair Ibrahim Higazi, Long He, Jing Fang, et al.
Breast Cancer Research : BCR|July 7, 2025
Overexpression of TSG101 causes the development of adenosquamous mammary carcinomaRayane Dennaoui, Patrick D Rädler, Madison N Wicker, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 17, 2020
LION-PAW (lymphadenectomy in ovarian neoplasm) sexual function assessment: a prospective sub-study of the LION trialAnnette Hasenburg, Jalid Sehouli, Bjoern Lampe, et al.
Iscience|December 4, 2023
TRAIL-dependent apoptosis of peritoneal mesothelial cells by NK cells promotes ovarian cancer invasionAnna Mary Steitz, Clarissa Schröder, Isabel Knuth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapseEric Pujade-Lauraine, Uwe Wagner, Elisabeth Aavall-Lundqvist, et al.
Molecular Oncology|October 25, 2018
Cell type-selective pathways and clinical associations of lysophosphatidic acid biosynthesis and signaling in the ovarian cancer microenvironmentSilke Reinartz, Sonja Lieber, Jelena Pesek, et al.
Pageof 21